scAAV2-Mediated Expression of Thioredoxin 2 and C3 Transferase Prevents Retinal Ganglion Cell Death and Lowers Intraocular Pressure in a Mouse Model of Glaucoma
Abstract
:1. Introduction
2. Results
2.1. Characteristics of scAAV2-Trx2-C3
2.2. scAAV2-Trx2-C3 Inhibits RhoA Activation and Cofilin Phosphorylation at Ser 3
2.3. scAAV2-Trx2-C3 Inhibits Oxidative Stress and Fibronectin Expression in Dexamethasone-Treated HeLa Cells
2.4. Intracameral Delivery of scAAV2-Trx2-C3 Lowers IOP in a Dexamethasone-Induced Mouse Model of Glaucoma
2.5. Intracameral Delivery of scAAV2-Trx2-C3 Inhibits Fibronectin/Alpha-SMA Expression in the Trabecular Meshwork of the Dexamethasone-Induced Mouse Model of Glaucoma
2.6. Intracameral Delivery of scAAV2-Trx2-C3 Protects Retinal Ganglion Cells in a Dexamethasone-Induced Mice Model of Glaucoma
3. Discussion
4. Materials and Methods
4.1. Antibodies and Chemicals
4.2. Animal Care
4.3. Construction of Viral Vector
4.4. Cell Culture
4.5. Real-Time RT-PCR
4.6. Western Blotting
4.7. Active RhoA Assay
4.8. ROS Measurement
4.9. TUNEL Assay
4.10. Immunohistochemistry
4.11. Intraocular Pressure Measurements and Dexamethasone Treatment of Mice
4.12. Intracameral Injection of scAAV2-GFP and scAAV2-Trx2-C3
4.13. Statistics and Image Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Data Availability Statement
Conflicts of Interest
References
- Davis, B.M.; Crawley, L.; Pahlitzsch, M.; Javaid, F.; Cordeiro, M.F. Glaucoma: The retina and beyond. Acta Neuropathol. 2016, 132, 807–826. [Google Scholar] [CrossRef] [PubMed]
- Coleman, A.L.; Brigatti, L. The glaucomas. Minerva Med. 2001, 92, 365–379. [Google Scholar] [CrossRef] [PubMed]
- Song, Y.K.; Lee, C.K.; Kim, J.; Hong, S.; Kim, C.Y.; Seong, G.J. Instability of 24-hour intraocular pressure fluctuation in healthy young subjects: A prospective, cross-sectional study. BMC Ophthalmol. 2014, 14, 127. [Google Scholar] [CrossRef] [PubMed]
- Sihota, R.; Shakrawal, J.; Sidhu, T.; Sharma, A.K.; Dada, T.; Pandey, V. Does TRABECULECTOMY meet the 10-10-10 challenge in PACG, POAG, JOAG and Secondary glaucomas? Int. Ophthalmol. 2020, 40, 1233–1243. [Google Scholar] [CrossRef]
- Phulke, S.; Kaushik, S.; Kaur, S.; Pandav, S.S. Steroid-induced Glaucoma: An Avoidable Irreversible Blindness. J. Curr. Glaucoma Pract. 2017, 11, 67–72. [Google Scholar]
- Weinreb, R.N.; Polansky, J.R.; Kramer, S.G.; Baxter, J.D. Acute effects of dexamethasone on intraocular pressure in glaucoma. Investig. Ophthalmol. Vis. Sci. 1985, 26, 170–175. [Google Scholar]
- Raber, T. Influence of prostaglandins on aqueous humour dynamics and intraocular pressure. Klin. Monbl. Augenheilkd. 2005, 222, 802–806. [Google Scholar] [CrossRef]
- Rohen, J.W.; Lutjen-Drecoll, E.; Flugel, C.; Meyer, M.; Grierson, I. Ultrastructure of the trabecular meshwork in untreated cases of primary open-angle glaucoma (POAG). Exp. Eye Res. 1993, 56, 683–692. [Google Scholar] [CrossRef]
- Hakim, A.; Guido, B.; Narsineni, L.; Chen, D.W.; Foldvari, M. Gene therapy strategies for glaucoma from IOP reduction to retinal neuroprotection: Progress towards non-viral systems. Adv. Drug Deliv. Rev. 2023, 196, 114781. [Google Scholar] [CrossRef]
- Sharif, N.A. Therapeutic Drugs and Devices for Tackling Ocular Hypertension and Glaucoma, and Need for Neuroprotection and Cytoprotective Therapies. Front. Pharmacol. 2021, 12, 729249. [Google Scholar] [CrossRef]
- Keller, K.E. Tunneling nanotubes and actin cytoskeleton dynamics in glaucoma. Neural Regen. Res. 2020, 15, 2031–2032. [Google Scholar] [CrossRef] [PubMed]
- Quinlan, R.A.; Sandilands, A.; Procter, J.E.; Prescott, A.R.; Hutcheson, A.M.; Dahm, R.; Gribbon, C.; Wallace, P.; Carter, J.M. The eye lens cytoskeleton. Eye 1999, 13, 409–416. [Google Scholar] [CrossRef] [PubMed]
- Soundararajan, A.; Ghag, S.A.; Vuda, S.S.; Wang, T.; Pattabiraman, P.P. Cathepsin K Regulates Intraocular Pressure by Modulating Extracellular Matrix Remodeling and Actin-Bundling in the Trabecular Meshwork Outflow Pathway. Cells 2021, 10, 2864. [Google Scholar] [CrossRef] [PubMed]
- Faralli, J.A.; Filla, M.S.; Peters, D.M. Role of Fibronectin in Primary Open Angle Glaucoma. Cells 2019, 8, 1518. [Google Scholar] [CrossRef]
- Mavlyutov, T.A.; Myrah, J.J.; Chauhan, A.K.; Liu, Y.; McDowell, C.M. Fibronectin extra domain A (FN-EDA) causes glaucomatous trabecular meshwork, retina, and optic nerve damage in mice. Cell Biosci. 2022, 12, 72. [Google Scholar] [CrossRef]
- An, D.; Chung-Wah-Cheong, J.; Yu, D.Y.; Balaratnasingam, C. Alpha-Smooth Muscle Actin Expression and Parafoveal Blood Flow Pathways Are Altered in Preclinical Diabetic Retinopathy. Investig. Ophthalmol. Vis. Sci. 2022, 63, 8. [Google Scholar] [CrossRef]
- Wilde, C.; Genth, H.; Aktories, K.; Just, I. Recognition of RhoA by Clostridium botulinum C3 exoenzyme. J. Biol. Chem. 2000, 275, 16478–16483. [Google Scholar] [CrossRef]
- Spiering, D.; Hodgson, L. Dynamics of the Rho-family small GTPases in actin regulation and motility. Cell Adh. Migr. 2011, 5, 170–180. [Google Scholar] [CrossRef]
- Kardash, E.; Reichman-Fried, M.; Maître, J.-L.; Boldajipour, B.; Papusheva, E.; Messerschmidt, E.-M.; Heisenberg, C.-P.; Raz, E. A role for Rho GTPases and cell-cell adhesion in single-cell motility in vivo. Nat. Cell Biol. 2010, 12, 47–53. [Google Scholar] [CrossRef]
- Marinissen, M.J.; Chiariello, M.; Gutkind, J.S. Regulation of gene expression by the small GTPase Rho through the ERK6 (p38 gamma) MAP kinase pathway. Genes Dev. 2001, 15, 535–553. [Google Scholar] [CrossRef]
- Embade, N.; Valeron, P.F.; Aznar, S.; Lopez-Collazo, E.; Lacal, J.C. Apoptosis induced by Rac GTPase correlates with induction of FasL and ceramides production. Mol. Biol. Cell 2000, 11, 4347–4358. [Google Scholar] [CrossRef] [PubMed]
- Pattabiraman, P.P.; Inoue, T.; Rao, P.V. Elevated intraocular pressure induces Rho GTPase mediated contractile signaling in the trabecular meshwork. Exp. Eye Res. 2015, 136, 29–33. [Google Scholar] [CrossRef]
- Wang, J.; Liu, X.; Zhong, Y. Rho/Rho-associated kinase pathway in glaucoma (Review). Int. J. Oncol. 2013, 43, 1357–1367. [Google Scholar] [CrossRef] [PubMed]
- Tanihara, H. New understanding and development of medical treatments for ocular diseases based upon molecular mechanisms. Nippon Ganka Gakkai Zasshi 2005, 109, 917–959; discussion 960–961, discussion 960–961. [Google Scholar] [PubMed]
- Tan, J.; Liu, G.; Zhu, X.; Wu, Z.; Wang, N.; Zhou, L.; Zhang, X.; Fan, N.; Liu, X. Lentiviral Vector-Mediated Expression of Exoenzyme C3 Transferase Lowers Intraocular Pressure in Monkeys. Mol. Ther. 2019, 27, 1327–1338. [Google Scholar] [CrossRef]
- Semenova, Y.; Bjorklund, G. Antioxidants and neurodegenerative eye disease. Crit. Rev. Food Sci. Nutr. 2023, 13, 1–19. [Google Scholar] [CrossRef]
- Goodman, D.; Ness, S. The Role of Oxidative Stress in the Aging Eye. Life 2023, 13, 837. [Google Scholar] [CrossRef]
- Liu, Q.; Liu, C.; Lei, B. siRNA Mediated Downregulation of RhoA Expression Reduces Oxidative Induced Apoptosis in Retinal Ganglion Cells. Curr. Mol. Med. 2023; online ahead of print. [Google Scholar]
- Hasan, A.A.; Kalinina, E.; Tatarskiy, V.; Shtil, A. The Thioredoxin System of Mammalian Cells and Its Modulators. Biomedicines 2022, 10, 1757. [Google Scholar] [CrossRef]
- Munemasa, Y.; Kwong, J.M.; Kim, S.H.; Ahn, J.H.; Caprioli, J.; Piri, N. Thioredoxins 1 and 2 protect retinal ganglion cells from pharmacologically induced oxidative stress, optic nerve transection and ocular hypertension. Adv. Exp. Med. Biol. 2010, 664, 355–363. [Google Scholar]
- Munemasa, Y.; Ahn, J.H.; Kwong, J.M.; Caprioli, J.; Piri, N. Redox proteins thioredoxin 1 and thioredoxin 2 support retinal ganglion cell survival in experimental glaucoma. Gene Ther. 2009, 16, 17–25. [Google Scholar] [CrossRef] [PubMed]
- Bulcha, J.T.; Wang, Y.; Ma, H.; Tai, P.W.L.; Gao, G. Viral vector platforms within the gene therapy landscape. Signal Transduct. Target Ther. 2021, 6, 53. [Google Scholar] [CrossRef] [PubMed]
- Foti, S.B.; Samulski, R.J.; McCown, T.J. Delivering multiple gene products in the brain from a single adeno-associated virus vector. Gene Ther. 2009, 16, 1314–1319. [Google Scholar] [CrossRef] [PubMed]
- Sarwar, S.; Bakbak, B.; Sadiq, M.A.; Sepah, Y.J.; Shah, S.M.; Ibrahim, M.; Do, D.V.; Nguyen, Q.D. Fusion Proteins: Aflibercept (VEGF Trap-Eye). Dev. Ophthalmol. 2016, 55, 282–294. [Google Scholar] [PubMed]
- de Oliveira Dias, J.R.; de Andrade, G.C.; Novais, E.A.; Farah, M.E.; Rodrigues, E.B. Fusion proteins for treatment of retinal diseases: Aflibercept, ziv-aflibercept, and conbercept. Int. J. Retina Vitreous 2016, 2, 3. [Google Scholar] [CrossRef]
- Heier, J.S.; Khanani, A.M.; Ruiz, C.Q.; Basu, K.; Ferrone, P.J.; Brittain, C.; Figueroa, M.S.; Lin, H.; Holz, F.G.; Patel, V.; et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): Two randomised, double-masked, phase 3, non-inferiority trials. Lancet 2022, 399, 729–740. [Google Scholar] [CrossRef] [PubMed]
- Raj, D.; Davidoff, A.M.; Nathwani, A.C. Self-complementary adeno-associated viral vectors for gene therapy of hemophilia B: Progress and challenges. Expert Rev. Hematol. 2011, 4, 539–549. [Google Scholar] [CrossRef]
- Lee, S.H.; Sim, K.S.; Kim, C.Y.; Park, T.K. Transduction Pattern of AAVs in the Trabecular Meshwork and Anterior-Segment Structures in a Rat Model of Ocular Hypertension. Mol. Ther. Methods Clin. Dev. 2019, 14, 197–205. [Google Scholar] [CrossRef]
- Mendell, J.R.; Al-Zaidy, S.A.; Rodino-Klapac, L.R.; Goodspeed, K.; Gray, S.J.; Kay, C.N.; Boye, S.L.; Boye, S.E.; George, L.A.; Salabarria, S.; et al. Current Clinical Applications of In Vivo Gene Therapy with AAVs. Mol. Ther. 2021, 29, 464–488. [Google Scholar] [CrossRef]
- Borras, T. Advances in glaucoma treatment and management: Gene therapy. Investig. Ophthalmol. Vis. Sci. 2012, 53, 2506–2510. [Google Scholar] [CrossRef]
- Razi Soofiyani, S.; Baradaran, B.; Lotfipour, F.; Kazemi, T.; Mohammadnejad, L. Gene therapy, early promises, subsequent problems, and recent breakthroughs. Adv. Pharm. Bull. 2013, 3, 249–255. [Google Scholar] [PubMed]
- Auricchio, A.; Rolling, F. Adeno-associated viral vectors for retinal gene transfer and treatment of retinal diseases. Curr. Gene Ther. 2005, 5, 339–348. [Google Scholar] [CrossRef] [PubMed]
- Overby, D.R.; Clark, A.F. Animal models of glucocorticoid-induced glaucoma. Exp. Eye Res. 2015, 141, 15–22. [Google Scholar] [CrossRef] [PubMed]
- Qi, X.; Lewin, A.S.; Sun, L.; Hauswirth, W.W.; Guy, J. Suppression of mitochondrial oxidative stress provides long-term neuroprotection in experimental optic neuritis. Investig. Ophthalmol. Vis. Sci. 2007, 48, 681–691. [Google Scholar] [CrossRef]
- Adornetto, A.; Russo, R.; Parisi, V. Neuroinflammation as a target for glaucoma therapy. Neural Regen. Res. 2019, 14, 391–394. [Google Scholar] [CrossRef]
- Hu, X.; Zhuang, D.; Zhang, R.; Sun, X.; Lu, Q.; Dai, Y. The small molecule inhibitor PR-619 protects retinal ganglion cells against glutamate excitotoxicity. Neuroreport 2020, 31, 1134–1141. [Google Scholar] [CrossRef]
- Kuo, C.Y.; Liu, C.J. Neuroprotection in Glaucoma: Basic Aspects and Clinical Relevance. J. Pers. Med. 2022, 12, 1884. [Google Scholar] [CrossRef]
- Gossman, C.A.; Christie, J.; Webster, M.K.; Linn, D.M.; Linn, C.L. Neuroprotective Strategies in Glaucoma. Curr. Pharm. Des. 2016, 22, 2178–2192. [Google Scholar] [CrossRef]
- Grawe, A.; Stein, V. Linker Engineering in the Context of Synthetic Protein Switches and Sensors. Trends Biotechnol. 2021, 39, 731–744. [Google Scholar] [CrossRef]
- Reddy Chichili, V.P.; Kumar, V.; Sivaraman, J. Linkers in the structural biology of protein-protein interactions. Protein Sci. 2013, 22, 153–167. [Google Scholar] [CrossRef]
- Shirley, M. Faricimab: First Approval. Drugs 2022, 82, 825–830. [Google Scholar] [CrossRef] [PubMed]
- Nicolo, M.; Ferro Desideri, L.; Vagge, A.; Traverso, C.E. Faricimab: An investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin. Investig. Drugs 2021, 30, 193–200. [Google Scholar] [CrossRef] [PubMed]
- Keller, K.E.; Peters, D.M. Pathogenesis of glaucoma: Extracellular matrix dysfunction in the trabecular meshwork-A review. Clin. Exp. Ophthalmol. 2022, 50, 163–182. [Google Scholar] [CrossRef] [PubMed]
- Hill, L.J.; Ahmed, Z.; Logan, A. Decorin treatment for reversing trabecular meshwork fibrosis in open-angle glaucoma. Neural Regen. Res. 2016, 11, 922–923. [Google Scholar] [CrossRef] [PubMed]
- Prendes, M.A.; Harris, A.; Wirostko, B.M.; Gerber, A.L.; Siesky, B. The role of transforming growth factor beta in glaucoma and the therapeutic implications. Br. J. Ophthalmol. 2013, 97, 680–686. [Google Scholar] [CrossRef] [PubMed]
- Buffault, J.; Brignole-Baudouin, F.; Reboussin, E.; Kessal, K.; Labbé, A.; Parsadaniantz, S.M.; Baudouin, C. The Dual Effect of Rho-Kinase Inhibition on Trabecular Meshwork Cells Cytoskeleton and Extracellular Matrix in an In Vitro Model of Glaucoma. J. Clin. Med. 2022, 11, 1001. [Google Scholar] [CrossRef]
- Garnock-Jones, K.P. Ripasudil: First global approval. Drugs 2014, 74, 2211–2215. [Google Scholar] [CrossRef]
- Tezel, G. Oxidative stress in glaucomatous neurodegeneration: Mechanisms and consequences. Prog. Retin. Eye Res. 2006, 25, 490–513. [Google Scholar] [CrossRef]
- Izzotti, A.; Bagnis, A.; Sacca, S.C. The role of oxidative stress in glaucoma. Mutat. Res. 2006, 612, 105–114. [Google Scholar] [CrossRef]
- Kang, E.Y.-C.; Liu, P.-K.; Wen, Y.-T.; Quinn, P.M.J.; Levi, S.R.; Wang, N.-K.; Tsai, R.-K. Role of Oxidative Stress in Ocular Diseases Associated with Retinal Ganglion Cells Degeneration. Antioxidants 2021, 10, 1948. [Google Scholar] [CrossRef]
- Yuki, K.; Ozawa, Y.; Yoshida, T.; Kurihara, T.; Hirasawa, M.; Ozeki, N.; Shiba, D.; Noda, K.; Ishida, S.; Tsubota, K. Retinal ganglion cell loss in superoxide dismutase 1 deficiency. Investig. Ophthalmol. Vis. Sci. 2011, 52, 4143–4150. [Google Scholar] [CrossRef] [PubMed]
- Yang, M.; So, K.F.; Lam, W.C.; Yin Lo, A.C. Ferroptosis and glaucoma: Implications in retinal ganglion cell damage and optic nerve survival. Neural Regen. Res. 2023, 18, 545–546. [Google Scholar] [CrossRef] [PubMed]
- Yıldırım, Ö.; Ateş, N.A.; Ercan, B.; Muslu, N.; Ünlü, A.; Tamer, L.; Atik, U.; Kanık, A. Role of oxidative stress enzymes in open-angle glaucoma. Eye 2005, 19, 580–583. [Google Scholar] [CrossRef] [PubMed]
- Caprioli, J.; Munemasa, Y.; Kwong, J.M.; Piri, N. Overexpression of thioredoxins 1 and 2 increases retinal ganglion cell survival after pharmacologically induced oxidative stress, optic nerve transection, and in experimental glaucoma. Trans. Am. Ophthalmol. Soc. 2009, 107, 161–165. [Google Scholar] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kim, H.J.; Cha, S.; Choi, J.-S.; Lee, J.Y.; Kim, K.E.; Kim, J.K.; Kim, J.; Moon, S.Y.; Lee, S.H.S.; Park, K.; et al. scAAV2-Mediated Expression of Thioredoxin 2 and C3 Transferase Prevents Retinal Ganglion Cell Death and Lowers Intraocular Pressure in a Mouse Model of Glaucoma. Int. J. Mol. Sci. 2023, 24, 16253. https://doi.org/10.3390/ijms242216253
Kim HJ, Cha S, Choi J-S, Lee JY, Kim KE, Kim JK, Kim J, Moon SY, Lee SHS, Park K, et al. scAAV2-Mediated Expression of Thioredoxin 2 and C3 Transferase Prevents Retinal Ganglion Cell Death and Lowers Intraocular Pressure in a Mouse Model of Glaucoma. International Journal of Molecular Sciences. 2023; 24(22):16253. https://doi.org/10.3390/ijms242216253
Chicago/Turabian StyleKim, Hee Jong, Seho Cha, Jun-Sub Choi, Joo Yong Lee, Ko Eun Kim, Jin Kwon Kim, Jin Kim, Seo Yun Moon, Steven Hyun Seung Lee, Keerang Park, and et al. 2023. "scAAV2-Mediated Expression of Thioredoxin 2 and C3 Transferase Prevents Retinal Ganglion Cell Death and Lowers Intraocular Pressure in a Mouse Model of Glaucoma" International Journal of Molecular Sciences 24, no. 22: 16253. https://doi.org/10.3390/ijms242216253